Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic FindingsGlobeNewsWire • 12/17/25
Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026Seeking Alpha • 12/11/25
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 11/13/25
Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year?Zacks Investment Research • 11/13/25
Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched DiseaseInvestors Business Daily • 10/06/25
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety DataGlobeNewsWire • 10/05/25
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) MeetingGlobeNewsWire • 09/29/25
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) MeetingGlobeNewsWire • 09/23/25
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual ReviewGlobeNewsWire • 09/12/25